Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kamada Ltd. stock logo
KMDA
Kamada
$6.95
+4.8%
$6.58
$4.74
$9.16
$399.49M0.9490,460 shs136,507 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2.14
+0.9%
$2.21
$1.82
$3.09
$87.42M1.65152,375 shs119,139 shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$4.12
+2.5%
$4.33
$2.21
$19.71
$287.63M0.151.17 million shs815,301 shs
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
$9.62
+5.0%
$8.08
$5.14
$29.46
$517.50MN/A329,470 shs660,442 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kamada Ltd. stock logo
KMDA
Kamada
+4.83%+1.16%+3.89%-2.11%+31.13%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
+0.94%-0.47%-8.15%+1.42%-8.55%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
+2.49%-5.94%+0.24%-28.84%-60.76%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
+5.02%+5.37%+14.66%+25.59%+961,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kamada Ltd. stock logo
KMDA
Kamada
3.85 of 5 stars
3.43.00.00.03.41.73.1
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
2.0353 of 5 stars
0.05.00.00.02.60.81.9
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
4.0243 of 5 stars
4.52.00.00.03.65.00.6
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
1.9275 of 5 stars
3.50.00.00.02.80.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kamada Ltd. stock logo
KMDA
Kamada
2.75
Moderate Buy$14.67111.03% Upside
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
2.00
HoldN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
3.00
Buy$17.60327.18% Upside
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
3.00
Buy$56.50487.32% Upside

Current Analyst Ratings Breakdown

Latest ORMP, UPB, PHAT, and KMDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Kamada Ltd. stock logo
KMDA
Kamada
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/8/2025
Kamada Ltd. stock logo
KMDA
Kamada
Sidoti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $5.00
5/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $12.00
5/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $20.00
4/21/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
4/17/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$12.00 ➝ $10.00
4/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
4/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
3/21/2025
Kamada Ltd. stock logo
KMDA
Kamada
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kamada Ltd. stock logo
KMDA
Kamada
$167.24M2.39$0.39 per share17.90$4.25 per share1.64
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2M43.71N/AN/A$4.04 per share0.53
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$81.86M3.51N/AN/A($1.27) per share-3.24
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
$2.30M225.39N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kamada Ltd. stock logo
KMDA
Kamada
$8.28M$0.2924.8221.720.979.92%6.30%4.49%8/13/2025 (Estimated)
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$5.53M-$0.4419.45N/AN/AN/A-7.27%-6.20%8/13/2025 (Estimated)
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$201.59M-$5.24N/AN/AN/A-1,292.14%N/A-79.57%8/14/2025 (Estimated)
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/AN/A0.00N/AN/AN/AN/AN/A6/11/2025 (Estimated)

Latest ORMP, UPB, PHAT, and KMDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$0.03-$0.19-$0.16-$0.19N/A$2.00 million
5/14/2025Q1 2025
Kamada Ltd. stock logo
KMDA
Kamada
$0.07$0.07N/A$0.07$154.06 million$44.02 million
5/6/2025Q1 2025
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
-$0.49-$0.51-$0.02-$0.51$0.71 million$0.57 million
3/27/2025Q4 2024
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$0.03$0.01+$0.04$0.01N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kamada Ltd. stock logo
KMDA
Kamada
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/AN/AN/AN/AN/A
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/AN/AN/AN/AN/A

Latest ORMP, UPB, PHAT, and KMDA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/5/2025
Kamada Ltd. stock logo
KMDA
Kamada
--$0.203/17/20253/17/20254/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kamada Ltd. stock logo
KMDA
Kamada
N/A
4.84
2.73
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
27.08
27.08
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/A
5.73
5.68
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Kamada Ltd. stock logo
KMDA
Kamada
20.38%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
12.73%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
99.01%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/A

Insider Ownership

CompanyInsider Ownership
Kamada Ltd. stock logo
KMDA
Kamada
36.10%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
13.70%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
23.00%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
13.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kamada Ltd. stock logo
KMDA
Kamada
36057.48 million36.73 millionOptionable
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1040.85 million34.79 millionOptionable
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
11069.81 million51.90 millionOptionable
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
3853.79 millionN/AN/A

Recent News About These Companies

Upstream Bio Appoints Stacy Price As CTO

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Kamada stock logo

Kamada NASDAQ:KMDA

$6.95 +0.32 (+4.83%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$6.94 0.00 (-0.07%)
As of 07:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$2.14 +0.02 (+0.94%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.20 +0.06 (+2.76%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Phathom Pharmaceuticals stock logo

Phathom Pharmaceuticals NASDAQ:PHAT

$4.12 +0.10 (+2.49%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.18 +0.05 (+1.33%)
As of 08:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Upstream Bio stock logo

Upstream Bio NASDAQ:UPB

$9.62 +0.46 (+5.02%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$9.67 +0.05 (+0.56%)
As of 05/27/2025 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.